Odaberite jezik

hr
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Hrvatski
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Koja nadoplata na račun vam bolje odgovara?

* Ne naplaćujemo proviziju za polaganje depozita na vaš račun

Pfizer

PFE.US $ 41.46 USD

-0.16 $ (-0.38%)

Potencijal rasta

Preporuka
se pregledava

Prihod od dividende

4.07%

1d
1t
1 mj.
6 mjes.
Cijelo vrijeme

Dodaj u košaricu

1 serija = 1 dionica

Iznos kupnje:

Brokerska provizija:

Provizija za prijenos:

Preporuka

Strong Buy

Rejting uspješnosti

DCF

40.34

ROE

0.15

ROA

0.06

P/S

4.76

P/B

3.16

Debt / Equity

0.56

Korporativne informacije

An American corporation Pfizer Inc. specializes in manufacturing pharmaceutical drugs, such as Diflucan, Celebrex, Viagra. The company is almost 170 years old, and its growth peak was at the end of the 20th century when new and highly efficient results of "Pfizer" developments entered the market. The beginning of the 19th century was the time of mergers and acquisitions with the largest one being with an Irish company Allergan. Up to now, the company's existence was based on several successful developments; however, in future, it aims at abandoning this strategy and start investing in biotechnologies, for which purpose it purchased Wyeth company. A special attention will be paid to biological drugs of natural origin that slow aging. According to statistics, Pfizer accounts for more than 6% of the global drug market - the company is the leader of its sector. The company capitalization amounts to $190 billion; in 2017, the net profit amounted to $13.7 billion with annual turnover facing a slight decrease. Earlier, the stocks had been falling in price for several years, probably, due to a prolonged reorganization of the company; however, since 2016, an upward trend has become visible. As far as the further destiny of the Pfizer stocks is concerned, analysts stick to moderately optimistic opinion connected with a clear viewpoint of Ian Read who became the President of the company in 2010. His whole career has been dedicated to Pfizer; he got the highest position on the back of reorganization, has completed it and returned the company back to high financial results.


Prijavite se kako biste primali ideje za ulaganje analitičara društva Freedom Finance

Jedanput tjedno slat ćemo Vam poruku e-pošte koja sadrži samo najrelevantnije i najvažnije informacije

Čestitamo!

Sada ćete uvijek biti svjesni u koje dionice je isplativije ulagati